GSK has completed its $2 billion acquisition of Canadian biotech company Bellus Health. The deal provides GSK with access to camlipixant, a drug in phase 3 trials for refractory chronic cough. Bellus Health shareholders approved the acquisition on June 16.
- GSK (NYSE:GSK) has formally closed its $2B acquisition of Canadian biotech Bellus Health (NASDAQ:BLU).
- Bellus (BLU) shareholders approved the deal on June 16.
- The deal, announced in April, gives the UK drug giant access to camlipixant, currently in a phase 3 trial for refractory chronic cough.
Source: SeekingAlpha